Serrapeptase Use During Breastfeeding

Introduction to Serrapeptase Safety

• When medications have insufficient data rather than evidence of harm, the standard approach is to avoid them in breastfeeding women and consider alternative drugs, as recommended by the Annals of the Rheumatic Diseases 1, 2

Clinical Decision Making

• The American Academy of Pediatrics and other guideline societies suggest that preference should be given to medications with established safety profiles during lactation, particularly those that have been studied and show minimal transfer to breast milk, with drugs having a relative infant dose <10% of the maternal dose considered preferred options 4
• The fundamental principle in medication use during breastfeeding is weighing risk versus benefit, where the potential risk of drug therapy must be balanced against the risk of untreated maternal symptoms, according to Praxis Medical Insights 3

Monitoring and Alternative Approaches

• It is recommended to monitor infants for unusual symptoms, including changes in stool pattern, irritability, or poor feeding, if any medication is used during breastfeeding, as suggested by Praxis Medical Insights 4